A new vaccine for deadly EEHV (Elephant Endotheliotrophic Herpes Virus) is to begin a trial at Chester Zoo in the UK, with assistance from the University of Surrey. If the trials are successful the vaccine would be invaluable for zoos worldwide and for wild elephant populations.
Full article here: Vaccine trial for killer elephant virus begins
The virus was discovered in 1990 and formally characterised in 1999 by researchers at the Smithsonian Zoo in Washington DC. They linked 10 cases of a "highly fatal haemorrhagic disease" in young Asian and African elephants in zoos. In each case, they found "herpes virus-like particles" in cells of dead elephants' hearts, livers and tongues.
Since then, the virus has been a zoo's worst nightmare. A recent study, led by Berlin-based veterinary scientist Sonia Jesus Fontes, calculated that it had caused 52% of the deaths of Asian elephants in European zoos since 1985. In North American zoos, it accounted for 50% of deaths since 1980.
It has now been detected in sanctuaries, safari parks and, more worryingly, in wild elephant herds in nine countries.
Groups of researchers around the world study EEHV, but Chester Zoo is now taking an important step with the vaccine trial, as the lead scientist behind its development, Prof Falko Steinbach from the University of Surrey, explains.
Full article here: Vaccine trial for killer elephant virus begins